Lv11
20 积分 2021-09-30 加入
Non‐small‐cell lung cancer with ERBB2 mutation in non‐tyrosine kinase domain benefits from pyrotinib: A case report
4小时前
待确认
Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non–Small Cell Lung Cancer: Implications for Precision Medicine
4小时前
已完结
A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations
5小时前
已完结
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial
4个月前
已完结
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
7个月前
已完结
Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies
10个月前
已完结
Updates in neuroendocrine neoplasms: From mechanisms to the clinic
1年前
已完结
Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites
1年前
已完结
SMARCA4: Current status and future perspectives in non-small-cell lung cancer
1年前
已完结
The Double-Cup Construct: A Novel Treatment Strategy for the Management of Paprosky IIIA and IIIB Acetabular Defects
1年前
已完结
皖公网安备34019202002308
